Effect of ziprasidone combined with low frequency repetitive transcranial magnetic stimulation on the levels of BNDF, IL-6 and Hcy and cognitive dysfunction in elderly patients with severe schizophrenia

ObjectiveTo investigate the effects of ziprasidone combined with low frequency repetitive transcranial magnetic stimulation on the levels of BNDF, IL-6 and Hcy, and cognitive dysfunction in elderly patients with severe schizophrenia.

MethodsOne hundred elderly patients with severe schizophrenia were randomly divided into the observation group and control group(50 cases in each group).The control group was treated with ziprasidone, and the observation group was treated with ziprasidone combined with low frequency repetitive transcranial magnetic stimulation for 2 months.The clinical efficacy, positive and negative symptom scale(PANSS) scores before and after treatment, repeatable battery for the assessment of neuropsychological status(RBANS) scores, levels of Hcy, BDNF and IL-6, and adverse reactions were compared between two groups.

ResultsCompared with before treatment, the PANSS scores decreased, the RBANS scores increased in two groups after treatment(P < 0.01).After treatment, the scores of PANSS in observation group was lower than that in control group(P < 0.01), and the scores of RBANS in observation group was higher than that in control group(P < 0.01).Compared with before treatment, the serum level of BDNF increased, the levels of IL-6 and Hcy decreased in two groups after treatment(P < 0.01).After treatment, the serum level of BDNF in observation group was higher than that in control group, and the levels of IL-6 and Hcy in observation group was lower than that in control group(P < 0.01).The effective rate in observation group(96.00%) was higher than that in control group(84.00%) (P < 0.05).There was no statistical significance in the incidence rate of adverse reactions between two groups(P>0.05).

ConclusionsZiprasidone combined with low frequency repetitive transcranial magnetic stimulation is effective in the treatment of elderly patients with severe schizophrenia.It can improve cognitive impairment, reduce the levels of IL-6 and Hcy, and improve the level of BDNF.It is safe and worthy of promotion.